Securities Code: 002422 Securities Abbreviation: Kelun Pharmaceutical Announcement No.: 2026-040 Sichuan Kelun Pharmaceutical Co., Ltd. Announcement on the Progress of Company Share Repurchase
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and there are no false records, misleading statements, or major omissions.
Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has had the proposal regarding the company's share repurchase plan deliberated and approved by the eleventh meeting of the eighth Board of Directors held on January 4, 2026. On January 6, 2026, the Company disclosed the "Resolution Announcement of the Eleventh Meeting of the Eighth Board of Directors" and the "Announcement on the Company's Share Repurchase Plan and Repurchase Report" on the designated information disclosure website of the Shenzhen Stock Exchange (www.cninfo.com.cn), and in the Securities Times, Shanghai Securities News, Securities Daily, and China Securities Journal.
According to the "Announcement on the Company's Share Repurchase Plan and Repurchase Report" (hereinafter referred to as the "Plan"), the Company intends to repurchase its shares through centralized bidding transactions on the Shenzhen Stock Exchange. Due to the Company's implementation of the 2025 annual equity distribution, in accordance with the provisions of the Plan, the repurchase price in the Company's share repurchase plan has been adjusted from not exceeding 35 yuan/share to not exceeding 34.53 yuan/share. The adjusted upper limit of the repurchase price will be effective from May 11, 2026. According to the Plan, the total repurchase amount is not less than RMB 50,000,000.00 (inclusive) and not more than RMB 100,000,000.00 (inclusive). After adjustment, calculated based on the lower limit of the repurchase amount, the estimated number of shares to be repurchased is approximately 1,448,016 shares, accounting for about 0.09% of the Company's total share capital at the time of the Plan disclosure; calculated based on the upper limit of the repurchase amount, the estimated number of shares to be repurchased is approximately 2,896,032 shares, accounting for about 0.18% of the Company's total share capital at the time of the Plan disclosure.